SecBot SecBot
Biotech Drug Report Generated Sep 12, 2026

ZEVASKYN

ABEO·ABEONA THERAPEUTICS INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already approved and commercially launched in the U.S. (April 2025).
Why 4/10
ZEVASKYN is already FDA-approved and commercially launched, so the defining binary catalyst (the approval decision) has passed. There is no pending PDUFA or pivotal readout in the next ~12 months. The next catalysts are commercial execution metrics and the CMS NTAP designation (October 2026), which are not hard binary events. Per the rubric, an approved drug with no pending regulatory decision scores 3-5.
Actionable Insight NEUTRAL

ZEVASKYN is already approved and generating revenue, so the binary approval catalyst is behind it. Watch quarterly commercial metrics (patient starts, revenue growth, treatment center expansion) and the CMS NTAP designation effective October 2026 for reimbursement tailwinds. The stock's ~214% implied upside to the mean analyst target reflects optimism on commercial ramp, but ongoing cash burn and EPS misses warrant caution.

Price Chart

Loading chart...

Executive Summary

ZEVASKYN (prademagene zamikeracel, also known as pz-cel) is Abeona Therapeutics' first-in-class autologous cell-sheet gene therapy approved by the FDA on April 28, 2025 for recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic skin disorder. It is the first and only FDA-approved treatment for RDEB. Commercial launch is underway with growing revenue ($11.4M in Q2 2026, up 31% QoQ) and five Qualified Treatment Centers activated. The stock trades at ~$5.42 with a consensus analyst price target of ~$18.86 (214% implied upside), but the company remains unprofitable with widening net losses and no imminent binary catalyst since the approval decision has passed.

How It Works

ZEVASKYN is a personalized gene therapy made from the patient's own skin cells. Doctors take a small sample of the patient's skin, genetically modify the cells in a lab to produce functional type VII collagen (the protein missing in RDEB), grow them into sheets, and surgically graft them onto the patient's wounds. This helps wounds heal and close.

Trial Status

ZEVASKYN was approved by the FDA on April 28, 2025 based on a Phase 3 open-label clinical trial (NCT04227106) that demonstrated durable wound healing. The therapy is now commercially available in the U.S. through a network of Qualified Treatment Centers.

The Two-Sided Case

▲ Bull Case5
First and only FDA-approved treatment for RDEB, a severe rare disease with no prior approved therapies, strong orphan drug positioning
Commercial revenue growing rapidly: $2.4M in Q4 2025 → $8.7M in Q1 2026 → $11.4M in Q2 2026 (31% QoQ growth)
Analyst consensus strongly bullish: 11 of 12 analysts rate Buy/Strong Buy, mean price target $18.86 (~214% upside from ~$5.42)
CMS NTAP designation effective October 2026 should improve hospital reimbursement and accelerate adoption
Institutional ownership is broad with 74 tracked holders including BlackRock ($20.7M) and Vanguard ($13.7M) as of Q2 2026
▼ Bear Case5
Company is unprofitable with widening net losses: -$17.1M in Q1 2026 and -$20.2M in Q2 2026, with EPS misses
ZEVASKYN is an autologous cell therapy requiring a complex, individualized manufacturing process, scalability and capacity constraints could limit revenue growth
As a surgically grafted cell-sheet therapy, patient access is limited to specialized treatment centers (only 5 activated so far)
Insider sales (mostly tax-withholding) and elevated short volume ratio (~67%) suggest caution among some market participants
No imminent binary catalyst to drive a sharp re-rating, the stock may drift on quarterly commercial execution

Upcoming Catalysts

  • CMS New Technology Add-on Payment (NTAP) designation effective October 2026, improving hospital reimbursement
  • Quarterly earnings reports tracking commercial revenue growth and patient starts
  • Expansion of Qualified Treatment Center network beyond current five sites

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ABEONA THERAPEUTICS INC. 8-K ABEO ·Originating report

Sources · 7

Hover a chip for the title
1 fda.gov2 fda.gov3 debra.org4 chop.edu5 drugs.com6 asgct.org7 pmc.ncbi.nlm.nih.gov